Univest
Univest
  • Markets

Top Smaller Pharma Stocks Compared: Alembic Pharmaceuticals vs Granules India vs Marksans Pharma vs Caplin Point vs Aarti Drugs on Price, Valuation, Q2 FY27 Results and Risks

  • November 19, 2026
  • Posted by: Kunal Singla
  • Category: Best Stocks
No Comments
Top Smaller Pharma Stocks Compared: Alembic Pharmaceuticals vs Granules India vs Marksans Pharma vs Caplin Point vs Aarti Drugs on Price, Valuation, Q2 FY27 Results and Risks

Previous close: Alembic Pharmaceuticals Rs 112.41, Granules India Rs 797.50, Marksans Pharma Rs 294.50, Caplin Point Rs 2,085.30, Aarti Drugs Rs 505.75.

Quick Answer

This smaller pharma stocks compared snapshot checks five names on price, valuation and Q2 FY27 results: Alembic Pharmaceuticals, Granules India, Marksans Pharma, Caplin Point and Aarti Drugs. Granules India is the largest by market capitalisation at Rs 22,937 crore. Caplin Point reports the highest return on equity at 17.88%. Smaller pharma names earn from different products and markets, so read each multiple next to margins and returns.

Smaller pharma stocks compared here means Alembic Pharmaceuticals, Granules India, Marksans Pharma, Caplin Point and Aarti Drugs on one page, checked on previous close, market value, valuation and the latest quarterly numbers. The group covers two generic drug makers, an ingredients and finished dose maker, a Latin America focused maker and an ingredients maker, which is exactly why a side-by-side look helps.

All five companies have filed their September 2026 quarter, so every result below is Q2 FY27. Smaller pharma stocks follow product approvals, export demand and pricing, so a glance at the Nifty Pharma page and the Sensex page before you read the tables gives useful backdrop.

Click Here – Get Free Investment Predictions

Table of Contents

Toggle
  • Smaller Pharma Stocks Compared: Five Names on the List
  • Smaller Pharma Stocks Valuation: Multiples, Returns and Payouts
  • Smaller Pharma Stocks Q2 FY27 Results: Revenue and Profit Check
    • Alembic Pharmaceuticals Results Snapshot
    • Granules India Results Snapshot
    • Marksans Pharma Results Snapshot
    • Caplin Point Results Snapshot
    • Aarti Drugs Results Snapshot
  • Smaller Pharma Stocks Compared Two at a Time: Three Pairings
    • Alembic Pharmaceuticals vs Marksans Pharma
    • Granules India vs Aarti Drugs
    • Caplin Point vs Alembic Pharmaceuticals
  • Best Smaller Pharma Stocks for Each Type of Investor
  • What Is Driving Smaller Pharma Stocks Right Now?
  • Risks to Weigh When You Compare Smaller Pharma Stocks
  • How to Compare Smaller Pharma Stocks and Build a Shortlist
  • Conclusion: Smaller Pharma Stocks Compared at a Glance
  • Frequently Asked Questions on Smaller Pharma Stocks Compared
    • Which are the top smaller pharma stocks compared in this article?
    • Which smaller pharma stock has the highest market capitalisation?
    • Which of these smaller pharma stocks has the lowest price to earnings ratio?
    • Which smaller pharma stock has the highest return on equity?
    • How did smaller pharma stocks perform in Q2 FY27 results?
    • What are the main risks when you compare smaller pharma stocks?
    • Which metrics matter most when you compare Smaller Pharma stocks?
    • Which is the best smaller pharma stock to buy among these five?

Smaller Pharma Stocks Compared: Five Names on the List

The smaller pharma stocks compared here are Alembic Pharmaceuticals, Granules India, Marksans Pharma, Caplin Point and Aarti Drugs. Granules India is the largest by market capitalisation at Rs 22,937 crore. Previous closes run from Rs 112.41 for Alembic Pharmaceuticals to Rs 2,085.30 for Caplin Point, which is why a side-by-side look at value rather than price is more useful. This smaller pharma stocks compared list is the base for every table that follows.

Stock Previous close (Rs) Market cap (Rs crore)
Alembic Pharmaceuticals 112.41 20,576
Granules India 797.50 22,937
Marksans Pharma 294.50 14,471
Caplin Point 2,085.30 18,155
Aarti Drugs 505.75 4,566

A quick look at the business behind each ticker puts the numbers in context. Alembic Pharmaceuticals makes generic and specialty medicines, while Granules India makes pharmaceutical ingredients and finished doses. Marksans Pharma makes generic medicines for regulated markets, and Caplin Point makes and sells pharma products in Latin America and Africa. To compare smaller pharma stocks properly, line up price to earnings, return on equity and operating margin before forming a view.

Rounding out the group, Aarti Drugs makes active pharmaceutical ingredients. A fair smaller pharma stock comparison looks at what each company actually earns from, not only at the share price. An ingredients maker and a finished dose seller belong in separate mental boxes whenever you compare smaller pharma stocks fairly.

Smaller Pharma Stocks Valuation: Multiples, Returns and Payouts

Aarti Drugs trades at the lowest price to earnings ratio in this group at 19.96. Caplin Point reports the highest return on equity at 17.88%. Aarti Drugs has the lowest price to book value at 2.72. These smaller pharma stocks valuation readings come from the previous close and the latest reported financials. That is the idea behind this smaller pharma stocks compared table: price to earnings and return on equity sit side by side so a high or low reading stands out at once.

Stock Price to earnings Price to book ROE (%) Dividend yield (%) Debt to equity
Alembic Pharmaceuticals 24.50 3.46 14.20 1.15 0.26
Granules India 32.14 3.49 10.87 0.19 0.17
Marksans Pharma 25.58 4.34 16.80 0.28 0.14
Caplin Point 25.93 4.65 17.88 0.33 0.00
Aarti Drugs 19.96 2.72 13.61 0.40 0.37

Price to earnings, return on equity, debt to equity and dividend yield give the clearest picture of valuation, returns and balance sheet room across the five names. Earnings per share and book value per share are the building blocks behind price to earnings and price to book, so a glance at both in each filing is time well spent. A simple smaller pharma stock comparison like this one is only as useful as the context behind it, which is why operating margin is worth checking as well.

In this group, price to earnings runs from 19.96 for Aarti Drugs to 32.14 for Granules India. Alembic Pharmaceuticals offers the highest dividend yield at 1.15%. Industry price to earnings readings differ by sub-sector: Alembic Pharmaceuticals, Granules India, Marksans Pharma and Caplin Point at 40.55; Aarti Drugs at 40.13. The industry price to earnings is a handy anchor: a stock above it is priced for faster growth, and one below it is priced for steadier earnings. A well-built smaller pharma stock comparison also notes that one approval can move quarterly numbers. Run the same smaller pharma stock comparison on your own watchlist and the pattern in these numbers will be easier to spot.

Smaller Pharma Stocks Q2 FY27 Results: Revenue and Profit Check

All of the five smaller pharma stocks compared have filed Q2 FY27 numbers. Alembic Pharmaceuticals posted the fastest revenue growth at 36.6% year on year. Aarti Drugs showed the sharpest rise in net profit at 83.3%. Read revenue first and quarterly profit second, since the two together show how much of the growth reaches shareholders. Treat the Q2 FY27 numbers in this smaller pharma stocks compared review as a snapshot of one quarter, not a verdict on any pharma company.

Stock Q2 FY27 revenue (Rs crore) Q2 FY26 revenue (Rs crore) Q2 FY27 net profit (Rs crore) Q2 FY26 net profit (Rs crore)
Alembic Pharmaceuticals 2,619 1,917 333.9 183.7
Granules India 1,571 1,296 181.8 130.6
Marksans Pharma 958.3 742.0 143.5 99.1
Caplin Point 663.1 564.4 182.3 160.2
Aarti Drugs 828.8 652.9 82.8 45.2

Alembic Pharmaceuticals Results Snapshot

In the September 2026 quarter, Alembic Pharmaceuticals booked revenue of Rs 2,619 crore against Rs 1,917 crore in the same quarter last year, a rise of 36.6%. Net profit rose 81.8% to Rs 333.9 crore from Rs 183.7 crore. Operating margin expanded to 22.2% from 17.0% a year ago. Earnings per share for the quarter rose to Rs 17.05 from Rs 9.40.

Granules India Results Snapshot

Granules India’s Q2 FY27 top line stood at Rs 1,571 crore, versus Rs 1,296 crore in Q2 FY26, a rise of 21.2%. Net profit rose 39.2% to Rs 181.8 crore from Rs 130.6 crore. Operating margin expanded to 22.6% from 21.4% a year ago. Earnings per share for the quarter rose to Rs 7.03 from Rs 5.38.

Marksans Pharma Results Snapshot

Marksans Pharma reported Q2 FY27 revenue of Rs 958.3 crore, compared with Rs 742.0 crore a year earlier, a rise of 29.2%. Net profit rose 44.8% to Rs 143.5 crore from Rs 99.1 crore. Operating margin expanded to 24.7% from 23.1% a year ago. Earnings per share for the quarter rose to Rs 3.11 from Rs 2.17.

Caplin Point Results Snapshot

In the September 2026 quarter, Caplin Point booked revenue of Rs 663.1 crore against Rs 564.4 crore in the same quarter last year, a rise of 17.5%. Net profit rose 13.8% to Rs 182.3 crore from Rs 160.2 crore. Earnings per share for the quarter rose to Rs 23.37 from Rs 20.25.

Aarti Drugs Results Snapshot

Aarti Drugs’ Q2 FY27 top line stood at Rs 828.8 crore, versus Rs 652.9 crore in Q2 FY26, a rise of 26.9%. Net profit rose 83.3% to Rs 82.8 crore from Rs 45.2 crore. Operating margin expanded to 16.7% from 12.9% a year ago. Earnings per share for the quarter rose to Rs 9.07 from Rs 4.95.

Approvals, volumes and pricing shape earnings, so each name needs a look at its own results, so profit can look different from revenue in a single quarter. That is why a smaller pharma stock comparison works best when revenue and profit are read together across two or three quarters. Used this way, a smaller pharma stocks compared review becomes a map of the sector rather than a price list. When you compare smaller pharma stocks after each result season, track how operating margin changes from one quarter to the next.

Smaller Pharma Stocks Compared Two at a Time: Three Pairings

Readers rarely want a five-way table and nothing else, so here are three head-to-head reads drawn from the same data. Use them as a quick way to compare smaller pharma stocks two at a time.

Alembic Pharmaceuticals vs Marksans Pharma

Alembic and Marksans both sell generic medicines in regulated markets. On price to earnings, Alembic Pharmaceuticals carries the lower multiple at 24.50 against 25.58 for Marksans Pharma. Marksans Pharma reports the higher return on equity, at 16.80% against 14.20% for Alembic Pharmaceuticals. For dividend income, Alembic Pharmaceuticals offers 1.15% against 0.28% at Marksans Pharma. Two generic makers with different mixes, so read margins next to valuation.

Granules India vs Aarti Drugs

Granules and Aarti Drugs both make active pharmaceutical ingredients. Aarti Drugs reports the higher return on equity, at 13.61% against 10.87% for Granules India. For dividend income, Aarti Drugs offers 0.40% against 0.19% at Granules India. In Q2 FY27, Aarti Drugs grew revenue faster, at 26.9% year on year against 21.2% for Granules India. Two ingredient makers with different scale, so compare returns first.

Caplin Point vs Alembic Pharmaceuticals

Caplin Point sells in Latin America and Africa, while Alembic sells in regulated markets. The two are close in size, with market capitalisations of Rs 18,155 crore for Caplin Point and Rs 20,576 crore for Alembic Pharmaceuticals. On price to earnings, Alembic Pharmaceuticals carries the lower multiple at 24.50 against 25.93 for Caplin Point. Caplin Point reports the higher return on equity, at 17.88% against 14.20% for Alembic Pharmaceuticals. Two makers with different regions, so read returns together.

Best Smaller Pharma Stocks for Each Type of Investor

Searching for the best smaller pharma stocks usually means different things to different readers. The table below shows who leads on each measure today, so you can pick the row that matches your goal. Any smaller pharma stocks compared table can mislead if you stop at one row, because each pharma company leads on a different measure.

If you care most about Start your research with The number
Lowest price to earnings Aarti Drugs 19.96
Highest return on equity Caplin Point 17.88%
Highest dividend yield Alembic Pharmaceuticals 1.15%
Lowest price to book value Aarti Drugs 2.72
Largest by market capitalisation Granules India Rs 22,937 crore
Fastest Q2 FY27 revenue growth Alembic Pharmaceuticals 36.6%
Sharpest Q2 FY27 net profit rise Aarti Drugs 83.3%

No single name tops every row, which is exactly why a smaller pharma stock comparison helps. Margins, returns and valuation point to different companies, so decide what matters most to you before you rank the numbers.

What Is Driving Smaller Pharma Stocks Right Now?

Smaller pharma stocks sit outside the largest drug makers, so readers study how mid-sized and small players earn from generics and ingredients. Knowing what moves approvals and export demand helps you compare smaller pharma stocks with the right questions in mind.

Product approvals, export demand and pricing decide earnings, so each maker follows its own market and product mix. A good smaller pharma stocks compared routine therefore tracks approvals, export demand and quarterly results.

Risks to Weigh When You Compare Smaller Pharma Stocks

Smaller Pharma stocks depend on demand, input costs, policy and the wider market mood. Valuations differ by company, so read each filing for order, volume and margin commentary before you compare them. Every smaller pharma stock comparison has blind spots, and for this group the biggest is approvals and export demand.

Because approvals, export demand and quarterly results drive these businesses, the most useful habit is to read the management commentary that comes with every result and note what is expected for the next quarter. Read together, the risk notes and the tables make this smaller pharma stocks compared guide a balanced starting point.

How to Compare Smaller Pharma Stocks and Build a Shortlist

Start by deciding which part of the drug chain you want exposure to, because each reads the market differently. Readers who follow approvals, export demand and quarterly results find the group easier to track. Done step by step, this smaller pharma stocks compared routine becomes repeatable rather than a one-off exercise.

Then check valuation and returns, because the five names rarely trade on the same multiple. An ingredients maker next to a generics seller shows how the business behind each price changes the numbers. Keep the shortlist of best smaller pharma stocks short enough that you can actually follow each company’s quarterly results. When you compare smaller pharma stocks again after new results, update only the rows that changed instead of starting over.

The Univest stock screener lets you filter smaller pharma stocks by market capitalisation, return on equity and price to earnings, and the app keeps live prices a tap away through the trading day. Come back to this smaller pharma stocks compared page after the next set of results to see which numbers have moved.

Check the Univest Screener for live smaller pharma stock data

Download the Univest iOS App or Univest Android App to track these smaller pharma stocks live.

Conclusion: Smaller Pharma Stocks Compared at a Glance

This smaller pharma stocks compared review on price, valuation and Q2 FY27 results shows that no single name wins every measure. Granules India leads on size and Caplin Point leads on return on equity, while the others bring their own strengths. Treat the smaller pharma stocks Q2 FY27 results and smaller pharma stocks valuation tables as a research starting point, then check the filings and speak to a SEBI-registered advisor before you invest. If you plan to compare smaller pharma stocks again next quarter, the same checklist of price to earnings, return on equity and operating margin will work.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

Frequently Asked Questions on Smaller Pharma Stocks Compared

Which are the top smaller pharma stocks compared in this article?

Ans. The smaller pharma stocks compared in this article are Alembic Pharmaceuticals, Granules India, Marksans Pharma, Caplin Point and Aarti Drugs. They are checked on previous close, market capitalisation, price to earnings, price to book, return on equity and the latest quarterly results, which gives you one tidy table to work from before you read any filing in detail.

Which smaller pharma stock has the highest market capitalisation?

Ans. Among the five names, Granules India has the highest market capitalisation at Rs 22,937 crore. Alembic Pharmaceuticals follows at Rs 20,576 crore. Because market capitalisation is simply share price multiplied by shares outstanding, it shifts daily, so confirm the live number before using it.

Which of these smaller pharma stocks has the lowest price to earnings ratio?

Ans. On smaller pharma stocks valuation, Aarti Drugs has the lowest price to earnings ratio among these smaller pharma stocks at 19.96, based on the latest reported earnings. Granules India sits at the other end at 32.14. A low multiple can reflect slower growth or higher risk as easily as a bargain, so read it next to growth and margins.

Which smaller pharma stock has the highest return on equity?

Ans. Caplin Point reports the highest return on equity in this group at 17.88%. The ratio measures profit earned for every rupee of shareholder money, which makes it a quick test of capital efficiency. One year can mislead, so look at several, and remember that borrowing can push the figure up.

How did smaller pharma stocks perform in Q2 FY27 results?

Ans. All of the five names have filed Q2 FY27 numbers in our data. Alembic Pharmaceuticals recorded the fastest revenue growth at 36.6% year on year. Aarti Drugs showed the sharpest net profit rise at 83.3%. For smaller pharma stocks Q2 FY27 results, each filing on the exchange website carries the full detail behind these figures.

What are the main risks when you compare smaller pharma stocks?

Ans. Smaller Pharma stocks depend on demand, input costs, policy and the wider market mood. Valuations differ by company, so read each filing for order, volume and margin commentary before you compare them. Keep an eye on approvals, export demand and quarterly results.

Which metrics matter most when you compare Smaller Pharma stocks?

Ans. Revenue growth, operating margin, return on equity and price to earnings matter most here. Compare each multiple with the company’s own approval pipeline. Read each filing for product and margin commentary.

Which is the best smaller pharma stock to buy among these five?

Ans. The best Smaller Pharma stock depends on which part of the drug chain you want exposure to, because the five names differ on all of these. On the numbers in this article, Granules India has the largest market capitalisation; Aarti Drugs has the lowest price to earnings; Caplin Point has the highest return on equity; Alembic Pharmaceuticals has the highest dividend yield. Each name wins on a different row, and this is educational content rather than advice. Build a shortlist from the tables, read the latest filings, and talk to a SEBI-registered advisor, because your own goals and risk appetite decide the right fit.



best smaller pharma stocks smaller pharma stocks compared smaller pharma stocks Q2 FY27 results smaller pharma stocks valuation
Author: Kunal Singla
Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.

Leave a Reply Cancel reply